RecruitingEarly phase 1NCT07568509
Rare condition
Arginine vasopressin deficiency
10
studies recruiting now
as of 7 Sept 2026
21
studies registered in total
as of 7 Sept 2026
4
countries with a recruiting site
as of 7 Sept 2026
6 May 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT07361263
Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency
RecruitingPhase 1NCT04789148
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
RecruitingNot applicableNCT07569861
Copeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia Syndrome
RecruitingPhase 2NCT06036004
Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 10 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Arginine vasopressin deficiency study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Arginine vasopressin deficiency
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Oxytocin (Orasthin)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).